Market capitalization | $7.12m |
Enterprise Value | $-570.00k |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.04 |
EV/Sales (TTM) EV/Sales | -0.05 |
P/S ratio (TTM) P/S ratio | 0.61 |
P/B ratio (TTM) P/B ratio | 0.37 |
Sales growth (TTM) Sales growth | 82.28% |
Turnover (TTM) Turnover | $11.68m |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
1 Analyst has issued a forecast Pulmatrix Inc:
1 Analyst has issued a forecast Pulmatrix Inc:
Mar '24 |
+/-
%
|
||
Turnover | 12 12 |
82%
82%
|
|
Gross income | 10 10 |
-
|
|
EBITDA | -8.06 -8.06 |
53%
53%
|
EBIT (operating result) EBIT | -9.41 -9.41 |
49%
49%
|
Net profit | -8.85 -8.85 |
52%
52%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
Head office | United States |
CEO | Teofilo Raad |
Employees | 22 |
Founded | 2015 |
Website | www.pulmatrix.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.